Haemonetics (HAE) Financials

$61.79 +2.23 (+3.75%)

Closing price 03:59 PM Eastern

Extended Trading

$57.26 -4.53 (-7.33%)

As of 07:25 PM Eastern

Annual Income Statements for Haemonetics

This table shows Haemonetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	3/28/2015	4/2/2016	4/1/2017	3/31/2018	3/30/2019	3/28/2020	4/3/2021	4/2/2022	4/1/2023	3/30/2024	3/29/2025
Net Income / (Loss) Attributable to Common Shareholders	17	-56	-26	46	55	77	79	43	115	118	168
Consolidated Net Income / (Loss)	17	-56	-26	46	55	77	79	43	115	118	168
Net Income / (Loss) Continuing Operations	17	-56	-26	46	55	77	79	43	115	118	168
Total Pre-Tax Income	31	-53	-27	60	74	87	73	64	141	152	212
Total Operating Income	41	-44	-19	56	84	103	90	81	156	165	222
Total Gross Profit	434	406	378	412	418	485	398	506	615	692	749
Total Revenue	910	909	886	904	968	988	870	993	1,169	1,309	1,361
Operating Revenue	910	909	886	904	968	988	870	993	1,169	1,309	1,361
Total Cost of Revenue	476	503	508	492	550	504	473	488	554	618	612
Operating Cost of Revenue	476	503	508	492	550	504	473	488	554	618	612
Total Operating Expenses	394	450	398	356	334	381	308	425	459	527	527
Selling, General & Admin Expense	337	317	302	317	273	282	275	340	377	432	437
Research & Development Expense	54	45	38	39	36	31	33	47	50	54	63
Amortization Expense	-	-	-	-	25	26	33	47	33	32	48
Impairment Charge	5.44	92	59	0.00	0.00	51	-	0.00	-0.38	8.42	2.39
Other Special Charges / (Income)	-2.92	-4.73	-	-	-	-	-	-	0.00	0.00	-23
Total Other Income / (Expense), net	-9.38	-9.47	-8.10	3.48	-9.91	-16	-17	-17	-15	-13	-9.75
Other Income / (Expense), net	-9.38	-9.47	-8.10	3.48	-9.91	-16	-17	-17	-15	-13	-9.75
Income Tax Expense	14	2.16	-1.21	14	19	11	-6.56	20	26	34	44
Basic Earnings per Share	$0.33	($1.09)	($0.51)	$0.86	$1.07	$1.51	$1.57	$0.85	$2.27	$2.32	$3.33
Weighted Average Basic Shares Outstanding	51.53M	50.91M	51.52M	52.76M	51.53M	50.69M	50.69M	51.05M	50.78M	50.71M	50.33M
Diluted Earnings per Share	$0.32	($1.09)	($0.51)	$0.85	$1.04	$1.48	$1.55	$0.84	$2.24	$2.29	$3.31
Weighted Average Diluted Shares Outstanding	52.09M	50.91M	51.52M	53.50M	52.94M	51.82M	51.29M	51.35M	51.42M	51.40M	50.73M
Weighted Average Basic & Diluted Shares Outstanding	51.20M	51M	51.50M	53M	51.21M	50.39M	50.95M	51.28M	50.54M	50.84M	48.04M

This table shows Haemonetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	12/27/2025
Net Income / (Loss) Attributable to Common Shareholders	41	25	31	20	38	34	37	58	34	39	45
Consolidated Net Income / (Loss)	41	25	31	20	38	34	37	58	34	39	45
Net Income / (Loss) Continuing Operations	41	25	31	20	38	34	37	58	34	39	45
Total Pre-Tax Income	52	33	44	23	47	45	50	71	45	51	60
Total Operating Income	54	35	46	30	40	52	59	71	54	58	67
Total Gross Profit	167	171	178	176	175	187	194	193	192	195	202
Total Revenue	311	318	336	343	336	346	349	331	321	327	339
Operating Revenue	311	318	336	343	336	346	349	331	321	327	339
Total Cost of Revenue	144	148	158	167	161	158	155	138	129	133	137
Operating Cost of Revenue	144	148	158	167	161	158	155	138	129	133	137
Total Operating Expenses	114	135	132	146	135	136	135	122	138	136	135
Selling, General & Admin Expense	93	115	112	122	108	107	106	115	111	102	109
Research & Development Expense	13	13	13	16	14	14	16	16	16	15	14
Amortization Expense	7.47	7.22	6.91	10	12	12	12	11	11	11	11
Impairment Charge	-	-	-	-	-	2.39	0.00	-	-	8.58	0.72
Total Other Income / (Expense), net	-2.07	-2.47	-1.95	-6.53	6.96	-6.99	-9.11	-0.60	-8.70	-7.21	-7.42
Other Income / (Expense), net	-2.07	-2.47	-1.95	-6.53	6.96	-6.99	-9.11	-0.60	-8.70	-7.21	-7.42
Income Tax Expense	11	7.92	13	3.05	8.34	11	12	13	11	13	15
Basic Earnings per Share	$0.81	$0.49	$0.62	$0.40	$0.75	$0.66	$0.75	$1.17	$0.71	$0.81	$0.96
Weighted Average Basic Shares Outstanding	50.54M	50.73M	50.77M	50.71M	50.94M	50.90M	50.29M	50.33M	48.11M	47.59M	46.79M
Diluted Earnings per Share	$0.80	$0.48	$0.61	$0.40	$0.74	$0.66	$0.74	$1.17	$0.70	$0.81	$0.95
Weighted Average Diluted Shares Outstanding	51.34M	51.40M	51.45M	51.40M	51.56M	51.24M	50.64M	50.73M	48.35M	47.66M	46.99M
Weighted Average Basic & Diluted Shares Outstanding	50.71M	50.74M	50.79M	50.84M	51.18M	50.22M	50.24M	48.04M	48.18M	46.81M	46.47M

This table details how cash moves in and out of Haemonetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	3/28/2015	4/2/2016	4/1/2017	3/31/2018	3/30/2019	3/28/2020	4/3/2021	4/2/2022	4/1/2023	3/30/2024	3/29/2025
Net Change in Cash & Equivalents	-32	-46	24	41	-11	-32	55	67	25	-106	128
Net Cash From Operating Activities	127	122	160	220	159	158	109	172	273	182	182
Net Cash From Continuing Operating Activities	127	122	160	220	159	158	109	172	273	182	182
Net Income / (Loss) Continuing Operations	17	-56	-26	46	55	77	79	43	115	118	168
Consolidated Net Income / (Loss)	17	-56	-26	46	55	77	79	43	115	118	168
Depreciation Expense	86	90	90	89	109	110	84	98	93	97	116
Amortization Expense	-	-	-	-	-	0.60	0.56	3.40	0.00	3.35	15
Non-Cash Adjustments To Reconcile Net Income	25	121	96	7.91	40	60	23	22	25	38	-19
Changes in Operating Assets and Liabilities, net	-0.72	-34	0.39	78	-46	-89	-78	5.89	40	-74	-97
Net Cash From Investing Activities	-122	-105	-73	-63	-116	-57	-425	-86	-144	-322	-162
Net Cash From Continuing Investing Activities	-122	-105	-73	-63	-116	-57	-425	-86	-144	-322	-162
Purchase of Property, Plant & Equipment	-122	-102	-76	-75	-119	-49	-37	-97	-191	-38	-39
Acquisitions	0.00	-3.00	-	0.00	0.00	-35	-435	-2.50	-2.85	-244	-151
Purchase of Investments	-	-	-	-	-	-	0.00	0.00	-33	-16	-17
Sale of Property, Plant & Equipment	0.45	0.64	2.82	2.76	2.81	17	1.82	2.02	1.61	1.81	23
Divestitures	-	0.00	0.00	9.00	0.00	9.81	45	11	0.85	1.50	43
Other Investing Activities, net	-	-	-	-	-	-	-	-	81	-28	-21
Net Cash From Financing Activities	-33	-63	-60	-121	-51	-131	367	-16	-100	38	109
Net Cash From Continuing Financing Activities	-33	-63	-60	-121	-51	-131	367	-16	-100	38	109
Repayment of Debt	-9.58	-22	-93	-62	-267	-13	-35	-18	-61	-72	-264
Repurchase of Common Equity	-39	-61	0.00	-100	-160	-175	0.00	0.00	-75	0.00	-225
Issuance of Debt	1.40	2.27	0.00	0.67	363	45	440	0.00	330	110	950
Other Financing Activities, net	14	18	33	40	13	12	-37	1.76	-295	0.48	-353
Effect of Exchange Rate Changes	-4.06	-0.01	-1.57	3.94	-3.32	-1.87	4.18	-2.98	-3.94	-3.19	-0.69
Cash Interest Paid	8.50	8.51	7.85	7.66	13	13	7.82	6.19	14	21	17
Cash Income Taxes Paid	11	7.83	6.96	9.08	8.21	12	12	24	18	53	49

This table details how cash moves in and out of Haemonetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	12/27/2025
Net Change in Cash & Equivalents	1.25	65	-157	-15	166	-45	22	-14	-14	3.53	67
Net Cash From Operating Activities	19	99	-0.54	64	-27	49	44	117	17	111	94
Net Cash From Continuing Operating Activities	19	99	-0.54	64	-27	49	44	117	17	111	94
Net Income / (Loss) Continuing Operations	41	25	31	20	38	34	37	58	34	39	45
Consolidated Net Income / (Loss)	41	25	31	20	38	34	37	58	34	39	45
Depreciation Expense	23	23	24	28	29	29	29	28	29	28	27
Amortization Expense	0.00	-	-	4.13	5.24	3.74	3.34	2.64	2.44	2.06	1.32
Non-Cash Adjustments To Reconcile Net Income	4.99	21	11	7.83	-19	12	3.27	-19	9.07	16	8.30
Changes in Operating Assets and Liabilities, net	-50	30	-67	4.12	-81	-30	-29	46	-57	26	12
Net Cash From Investing Activities	-15	-25	-269	-13	-139	-23	-17	18	-33	-30	-29
Net Cash From Continuing Investing Activities	-15	-25	-269	-13	-139	-23	-17	18	-33	-30	-29
Purchase of Property, Plant & Equipment	-7.68	-9.11	-15	-9.69	-5.66	-9.43	-8.55	-16	-3.75	-5.02	-6.35
Purchase of Investments	-6.00	-1.00	-3.13	-5.42	-0.54	-9.83	-3.18	-3.60	-18	-7.88	-10
Sale of Property, Plant & Equipment	0.40	0.52	0.34	0.55	20	0.19	0.25	2.45	0.30	0.12	0.43
Other Investing Activities, net	-1.98	-16	-7.65	-	-4.21	-2.54	-5.90	-8.46	-11	-18	-13
Net Cash From Financing Activities	-0.60	-7.17	109	-64	334	-75	1.38	-151	-2.44	-77	2.03
Net Cash From Continuing Financing Activities	-0.60	-7.17	109	-64	334	-75	1.38	-151	-2.44	-77	2.03
Repayment of Debt	-2.61	-3.51	-3.45	-64	-75	-65	-187	-1.59	-1.60	-1.60	-1.58
Other Financing Activities, net	2.02	-3.67	2.88	0.11	-356	0.21	3.09	0.14	-0.84	0.05	3.61
Effect of Exchange Rate Changes	-1.97	-1.53	3.02	-2.70	-1.45	4.20	-6.21	2.77	4.18	-0.77	0.81

This table presents Haemonetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	3/28/2015	4/2/2016	4/1/2017	3/31/2018	3/30/2019	3/28/2020	4/3/2021	4/2/2022	4/1/2023	3/30/2024	3/29/2025
Total Assets	1,485	1,319	1,239	1,237	1,275	1,267	1,820	1,860	1,935	2,196	2,451
Total Current Assets	558	488	510	521	576	604	694	756	770	769	935
Cash & Equivalents	161	115	140	180	169	137	192	259	284	179	307
Accounts Receivable	146	157	153	151	185	165	128	159	179	207	203
Inventories, net	211	187	177	161	194	270	323	293	259	317	365
Prepaid Expenses	40	29	41	29	27	31	51	44	47	66	60
Plant, Property, & Equipment, net	322	338	324	332	344	253	218	258	311	311	284
Total Noncurrent Assets	606	493	405	384	355	410	909	845	854	1,115	1,232
Goodwill	334	268	211	211	211	211	466	467	466	565	604
Intangible Assets	245	204	178	157	128	133	365	310	276	406	456
Noncurrent Deferred & Refundable Income Taxes	16	7.06	3.99	3.96	4.36	3.93	6.01	4.47	5.24	7.74	7.80
Other Noncurrent Operating Assets	11	14	12	12	12	62	71	63	107	136	164
Total Liabilities & Shareholders' Equity	1,485	1,319	1,239	1,237	1,275	1,267	1,820	1,860	1,935	2,196	2,451
Total Liabilities	659	598	499	485	607	680	1,088	1,110	1,117	1,236	1,630
Total Current Liabilities	189	186	211	385	236	275	253	442	252	300	578
Short-Term Debt	22	43	61	194	28	77	17	214	12	10	304
Accounts Payable	48	40	43	55	63	51	50	58	64	73	67
Current Employee Benefit Liabilities	51	36	44	70	53	49	48	49	64	81	59
Other Current Liabilities	68	67	64	66	92	98	139	121	112	136	148
Total Noncurrent Liabilities	471	412	288	100	371	405	835	668	865	935	1,052
Long-Term Debt	406	365	254	59	322	306	691	559	754	798	921
Noncurrent Deferred & Payable Income Tax Liabilities	33	21	12	6.53	20	11	44	29	36	63	63
Other Noncurrent Operating Liabilities	32	26	22	34	29	89	100	80	75	75	68
Total Equity & Noncontrolling Interests	826	722	740	752	668	587	732	749	818	960	821
Total Preferred & Common Equity	826	722	740	752	668	587	732	749	818	960	821
Total Common Equity	826	722	740	752	668	587	732	749	818	960	821
Common Stock	427	440	483	504	537	554	603	573	595	635	524
Retained Earnings	420	316	290	267	161	79	158	202	253	360	352
Accumulated Other Comprehensive Income / (Loss)	-22	-35	-33	-19	-30	-45	-30	-26	-30	-36	-55

This table presents Haemonetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	10/1/2022	12/31/2022	7/1/2023	9/30/2023	12/30/2023	6/29/2024	9/28/2024	12/28/2024	6/28/2025	9/27/2025	12/27/2025
Total Assets	1,865	1,878	1,962	2,011	2,200	2,541	2,525	2,531	2,462	2,442	2,491
Total Current Assets	716	706	802	866	765	979	956	1,006	913	900	944
Cash & Equivalents	241	224	286	351	194	344	299	321	293	296	363
Accounts Receivable	172	181	177	174	212	201	214	212	201	207	196
Inventories, net	255	256	289	286	304	374	382	360	361	336	321
Prepaid Expenses	48	45	50	55	55	59	61	113	59	60	63
Plant, Property, & Equipment, net	308	313	304	308	319	302	300	286	287	292	297
Total Noncurrent Assets	841	859	856	838	1,117	1,260	1,269	1,239	1,262	1,250	1,250
Goodwill	465	466	466	465	555	613	616	605	607	606	607
Intangible Assets	293	284	268	251	429	495	488	466	451	428	420
Noncurrent Deferred & Refundable Income Taxes	4.28	4.84	4.88	4.75	5.07	9.37	9.08	8.00	7.84	7.57	7.33
Other Noncurrent Operating Assets	80	103	117	117	127	142	156	160	196	208	216
Total Liabilities & Shareholders' Equity	1,865	1,878	1,962	2,011	2,200	2,541	2,525	2,531	2,462	2,442	2,491
Total Liabilities	1,136	1,102	1,098	1,118	1,257	1,636	1,646	1,624	1,580	1,593	1,579
Total Current Liabilities	262	227	237	264	262	260	274	253	531	548	540
Short-Term Debt	58	9.95	14	14	14	5.11	5.43	5.08	304	304	305
Accounts Payable	61	64	78	80	57	77	69	63	46	62	49
Current Employee Benefit Liabilities	45	52	33	46	59	41	49	46	36	48	52
Other Current Liabilities	98	101	112	125	132	137	150	139	146	134	134
Total Noncurrent Liabilities	874	875	861	853	995	1,376	1,372	1,371	1,048	1,045	1,040
Long-Term Debt	760	757	751	749	857	1,218	1,220	1,220	921	920	920
Noncurrent Deferred & Payable Income Tax Liabilities	36	40	37	35	62	65	63	61	59	58	56
Other Noncurrent Operating Liabilities	78	78	72	70	76	92	90	90	68	66	64
Total Equity & Noncontrolling Interests	729	776	865	894	943	905	879	907	882	849	911
Total Preferred & Common Equity	729	776	865	894	943	905	879	907	882	849	911
Total Common Equity	729	776	865	894	943	905	879	907	882	849	911
Common Stock	565	588	610	617	628	561	545	570	562	553	565
Retained Earnings	204	224	284	309	340	387	369	392	356	336	381
Accumulated Other Comprehensive Income / (Loss)	-40	-36	-30	-33	-24	-43	-35	-56	-36	-41	-35

This table displays calculated financial ratios and metrics derived from Haemonetics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	3/28/2015	4/2/2016	4/1/2017	3/31/2018	3/30/2019	3/28/2020	4/3/2021	4/2/2022	4/1/2023	3/30/2024	3/29/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-3.00%	-0.17%	-2.50%	2.01%	7.04%	2.16%	-11.94%	14.10%	17.67%	12.01%	3.95%
EBITDA Growth	-0.78%	-68.87%	70.59%	139.14%	22.95%	8.19%	-20.34%	4.45%	43.63%	7.99%	35.73%
EBIT Growth	-14.38%	-271.40%	48.56%	317.03%	23.48%	18.36%	-16.34%	-12.73%	122.23%	7.40%	39.64%
NOPAT Growth	-50.97%	-239.94%	55.89%	416.34%	45.46%	45.37%	7.79%	-43.73%	131.33%	0.23%	37.41%
Net Income Growth	-51.93%	-428.93%	52.74%	273.49%	20.73%	39.09%	3.85%	-45.42%	166.05%	1.87%	42.64%
EPS Growth	-52.24%	-440.63%	53.21%	266.67%	22.35%	42.31%	4.73%	-45.81%	166.67%	2.23%	44.54%
Operating Cash Flow Growth	-8.85%	-4.18%	31.08%	37.94%	-27.71%	-0.67%	-31.23%	58.32%	58.51%	-33.44%	-0.01%
Free Cash Flow Firm Growth	-63.19%	310.31%	78.99%	52.78%	-69.83%	169.56%	-395.87%	112.15%	137.50%	-277.05%	115.74%
Invested Capital Growth	0.95%	-7.22%	-9.83%	-9.70%	2.75%	-1.93%	49.82%	1.33%	2.84%	22.28%	9.43%
Revenue Q/Q Growth	-1.58%	1.78%	-1.59%	0.61%	1.65%	-1.08%	-1.52%	4.19%	3.49%	3.06%	-0.92%
EBITDA Q/Q Growth	-0.52%	-32.91%	-44.99%	96.92%	9.13%	-0.14%	-26.08%	39.06%	7.45%	-0.84%	14.74%
EBIT Q/Q Growth	-0.30%	-50.52%	-217.20%	563.45%	13.06%	0.16%	-40.37%	204.37%	13.94%	-5.72%	28.72%
NOPAT Q/Q Growth	-43.82%	-63.64%	-160.38%	492.40%	19.34%	-2.13%	-19.23%	26.15%	17.90%	-4.56%	23.13%
Net Income Q/Q Growth	-43.70%	-11.67%	-262.78%	361.19%	19.44%	-4.03%	-26.51%	91.98%	20.51%	-7.12%	28.92%
EPS Q/Q Growth	-44.83%	-10.10%	-259.38%	342.86%	20.93%	-2.63%	-26.89%	95.35%	21.08%	-7.29%	30.32%
Operating Cash Flow Q/Q Growth	3.11%	-1.66%	-10.47%	11.68%	-18.85%	19.46%	-29.19%	62.88%	4.42%	-7.87%	40.60%
Free Cash Flow Firm Q/Q Growth	414.00%	-37.61%	-0.29%	5.16%	-35.52%	2.06%	-413.61%	109.94%	51.56%	3.31%	152.55%
Invested Capital Q/Q Growth	-3.88%	-2.60%	-6.43%	-1.84%	1.99%	1.52%	48.46%	-0.60%	-1.47%	-1.91%	-3.98%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	47.72%	44.66%	42.71%	45.57%	43.15%	49.02%	45.70%	50.90%	52.63%	52.83%	55.04%
EBITDA Margin	12.88%	4.02%	7.03%	16.47%	18.92%	20.03%	18.12%	16.59%	20.25%	19.53%	25.18%
Operating Margin	4.45%	-4.84%	-2.19%	6.21%	8.63%	10.46%	10.31%	8.13%	13.35%	12.60%	16.30%
EBIT Margin	3.42%	-5.88%	-3.10%	6.60%	7.61%	8.82%	8.38%	6.41%	12.10%	11.60%	15.58%
Profit (Net Income) Margin	1.86%	-6.12%	-2.96%	5.04%	5.69%	7.74%	9.13%	4.37%	9.87%	8.98%	12.32%
Tax Burden Percent	54.22%	104.05%	95.60%	76.42%	74.72%	87.81%	108.99%	68.17%	81.61%	77.41%	79.07%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	45.78%	0.00%	0.00%	23.58%	25.28%	12.19%	-8.99%	31.83%	18.39%	22.59%	20.93%
Return on Invested Capital (ROIC)	2.02%	-2.92%	-1.41%	4.93%	7.46%	10.80%	9.41%	4.39%	9.94%	8.84%	10.54%
ROIC Less NNEP Spread (ROIC-NNEP)	0.04%	-11.78%	-6.83%	7.07%	1.63%	4.12%	4.58%	2.12%	7.54%	7.02%	9.54%
Return on Net Nonoperating Assets (RNNOA)	0.01%	-4.26%	-2.19%	1.18%	0.29%	1.40%	2.64%	1.47%	4.79%	4.39%	8.29%
Return on Equity (ROE)	2.03%	-7.18%	-3.60%	6.11%	7.75%	12.20%	12.05%	5.86%	14.73%	13.22%	18.83%
Cash Return on Invested Capital (CROIC)	1.08%	4.57%	8.93%	15.13%	4.75%	12.74%	-30.48%	3.07%	7.14%	-11.21%	1.53%
Operating Return on Assets (OROA)	2.08%	-3.81%	-2.15%	4.82%	5.86%	6.86%	4.72%	3.46%	7.45%	7.35%	9.13%
Return on Assets (ROA)	1.13%	-3.96%	-2.05%	3.68%	4.38%	6.02%	5.15%	2.36%	6.08%	5.69%	7.22%
Return on Common Equity (ROCE)	2.03%	-7.18%	-3.60%	6.11%	7.75%	12.20%	12.05%	5.86%	14.73%	13.22%	18.83%
Return on Equity Simple (ROE_SIMPLE)	2.05%	-7.70%	-3.55%	6.06%	8.24%	13.03%	10.86%	5.79%	14.11%	12.25%	20.43%
Net Operating Profit after Tax (NOPAT)	22	-31	-14	43	62	91	98	55	127	128	175
NOPAT Margin	2.41%	-3.38%	-1.53%	4.75%	6.45%	9.18%	11.24%	5.54%	10.90%	9.75%	12.89%
Net Nonoperating Expense Percent (NNEP)	1.98%	8.86%	5.43%	-2.14%	5.83%	6.68%	4.83%	2.27%	2.40%	1.82%	1.00%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	-	8.57%
Cost of Revenue to Revenue	52.28%	55.34%	57.29%	54.43%	56.85%	50.98%	54.30%	49.10%	47.37%	47.17%	44.96%
SG&A Expenses to Revenue	37.04%	34.90%	34.05%	35.02%	28.26%	28.53%	31.62%	34.25%	32.23%	32.98%	32.10%
R&D to Revenue	5.95%	4.95%	4.24%	4.34%	3.69%	3.12%	3.77%	4.71%	4.29%	4.16%	4.61%
Operating Expenses to Revenue	43.27%	49.50%	44.90%	39.36%	34.52%	38.56%	35.39%	42.77%	39.28%	40.23%	38.74%
Earnings before Interest and Taxes (EBIT)	31	-53	-27	60	74	87	73	64	141	152	212
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	117	36	62	149	183	198	158	165	237	256	343
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.76	2.49	2.85	5.20	6.68	8.65	7.78	4.35	5.10	4.52	3.87
Price to Tangible Book Value (P/TBV)	9.21	7.20	6.01	10.17	13.55	20.87	0.00	0.00	54.93	0.00	0.00
Price to Revenue (P/Rev)	2.50	1.97	2.38	4.33	4.61	5.14	6.54	3.29	3.57	3.31	2.33
Price to Earnings (P/E)	134.72	0.00	0.00	85.80	81.10	66.35	71.65	75.24	36.17	36.87	18.93
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.74%	0.00%	0.00%	1.17%	1.23%	1.51%	1.40%	1.33%	2.76%	2.71%	5.28%
Enterprise Value to Invested Capital (EV/IC)	2.33	2.06	2.50	4.82	5.47	6.40	4.98	2.99	3.58	3.12	2.35
Enterprise Value to Revenue (EV/Rev)	2.79	2.30	2.58	4.41	4.80	5.38	7.13	3.80	3.98	3.79	3.01
Enterprise Value to EBITDA (EV/EBITDA)	21.70	57.19	36.70	26.76	25.36	26.88	39.36	22.92	19.67	19.42	11.95
Enterprise Value to EBIT (EV/EBIT)	81.62	0.00	0.00	66.81	63.05	61.07	85.16	59.37	32.93	32.68	19.30
Enterprise Value to NOPAT (EV/NOPAT)	115.73	0.00	0.00	92.83	74.38	58.65	63.48	68.63	36.56	38.89	23.33
Enterprise Value to Operating Cash Flow (EV/OCF)	20.00	17.13	14.30	18.08	29.15	33.64	57.07	21.93	17.05	27.31	22.52
Enterprise Value to Free Cash Flow (EV/FCFF)	216.76	43.35	26.51	30.26	116.86	49.70	0.00	98.11	50.92	0.00	160.64
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.52	0.57	0.43	0.34	0.52	0.65	0.97	1.03	0.94	0.84	1.49
Long-Term Debt to Equity	0.49	0.51	0.34	0.08	0.48	0.52	0.94	0.75	0.92	0.83	1.12
Financial Leverage	0.31	0.36	0.32	0.17	0.18	0.34	0.58	0.70	0.64	0.62	0.87
Leverage Ratio	1.80	1.81	1.75	1.66	1.77	2.03	2.34	2.48	2.42	2.32	2.61
Compound Leverage Factor	1.80	1.81	1.75	1.66	1.77	2.03	2.34	2.48	2.42	2.32	2.61
Debt to Total Capital	34.12%	36.12%	29.85%	25.21%	34.39%	39.45%	49.16%	50.79%	48.36%	45.70%	59.87%
Short-Term Debt to Total Capital	1.72%	3.85%	5.79%	19.31%	2.72%	7.94%	1.18%	14.06%	0.74%	0.58%	14.84%
Long-Term Debt to Total Capital	32.41%	32.27%	24.06%	5.91%	31.68%	31.51%	47.98%	36.73%	47.61%	45.12%	45.03%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	65.88%	63.88%	70.15%	74.79%	65.61%	60.55%	50.84%	49.21%	51.65%	54.30%	40.13%
Debt to EBITDA	3.65	11.18	5.05	1.70	1.91	1.93	4.49	4.69	3.24	3.16	3.57
Net Debt to EBITDA	2.28	8.03	2.81	0.49	0.99	1.24	3.27	3.12	2.03	2.46	2.68
Long-Term Debt to EBITDA	3.47	9.99	4.07	0.40	1.76	1.54	4.38	3.40	3.19	3.12	2.69
Debt to NOPAT	19.47	-13.26	-23.19	5.91	5.61	4.21	7.23	14.05	6.01	6.33	6.98
Net Debt to NOPAT	12.16	-9.52	-12.91	1.71	2.90	2.70	5.27	9.34	3.78	4.93	5.23
Long-Term Debt to NOPAT	18.49	-11.85	-18.69	1.38	5.17	3.37	7.06	10.16	5.92	6.25	5.25
Altman Z-Score	3.45	2.97	3.80	6.16	5.86	5.89	4.16	2.77	3.59	3.42	2.39
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.96	2.63	2.42	1.35	2.44	2.20	2.74	1.71	3.06	2.56	1.62
Quick Ratio	1.62	1.47	1.38	0.86	1.50	1.10	1.26	0.95	1.84	1.28	0.88
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	12	48	86	132	40	107	-317	39	91	-162	25
Operating Cash Flow to CapEx	104.44%	119.75%	217.89%	305.87%	137.14%	494.68%	308.89%	182.31%	251.47%	281.85%	1,134.01%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.61	0.65	0.69	0.73	0.77	0.78	0.56	0.54	0.62	0.63	0.59
Accounts Receivable Turnover	5.87	6.00	5.72	5.95	5.76	5.64	5.95	6.92	6.90	6.79	6.65
Inventory Turnover	2.33	2.53	2.79	2.91	3.10	2.17	1.59	1.58	2.00	2.14	1.79
Fixed Asset Turnover	3.07	2.76	2.68	2.76	2.86	3.31	3.70	4.17	4.11	4.21	4.57
Accounts Payable Turnover	9.33	11.42	12.28	10.02	9.27	8.83	9.36	8.98	9.05	9.00	8.72
Days Sales Outstanding (DSO)	62.23	60.83	63.80	61.36	63.42	64.66	61.38	52.72	52.86	53.77	54.88
Days Inventory Outstanding (DIO)	156.73	144.47	130.85	125.27	117.83	168.25	228.94	230.38	182.12	170.40	203.52
Days Payable Outstanding (DPO)	39.11	31.97	29.71	36.44	39.36	41.32	39.01	40.66	40.32	40.57	41.86
Cash Conversion Cycle (CCC)	179.85	173.32	164.94	150.19	141.89	191.60	251.31	242.44	194.66	183.60	216.54
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,093	1,014	915	826	849	832	1,247	1,264	1,299	1,589	1,739
Invested Capital Turnover	0.84	0.86	0.92	1.04	1.16	1.18	0.84	0.79	0.91	0.91	0.82
Increase / (Decrease) in Invested Capital	10	-79	-100	-89	23	-16	415	17	36	290	150
Enterprise Value (EV)	2,544	2,087	2,285	3,984	4,643	5,323	6,209	3,778	4,656	4,964	4,093
Market Capitalization	2,276	1,794	2,110	3,910	4,462	5,078	5,694	3,263	4,175	4,335	3,175
Book Value per Share	$16.04	$14.19	$14.22	$14.08	$13.09	$11.67	$14.40	$14.66	$16.21	$18.90	$16.34
Tangible Book Value per Share	$4.80	$4.90	$6.75	$7.19	$6.46	$4.84	($1.97)	($0.55)	$1.51	($0.22)	($4.76)
Total Capital	1,254	1,130	1,054	1,006	1,018	970	1,439	1,523	1,584	1,768	2,046
Total Debt	428	408	315	254	350	382	708	774	766	808	1,225
Total Long-Term Debt	406	365	254	59	322	306	691	559	754	798	921
Net Debt	267	293	175	74	181	245	515	514	481	629	918
Capital Expenditures (CapEx)	122	102	73	72	116	32	35	94	109	64	16
Debt-free, Cash-free Net Working Capital (DFCFNWC)	230	231	220	151	199	268	265	268	245	300	354
Debt-free Net Working Capital (DFNWC)	391	346	360	331	368	406	457	528	530	479	660
Net Working Capital (NWC)	369	303	299	136	340	329	440	314	518	469	357
Net Nonoperating Expense (NNE)	5.08	25	13	-2.66	7.41	14	18	12	12	10	7.71
Net Nonoperating Obligations (NNO)	267	293	175	74	181	245	515	514	481	629	918
Total Depreciation and Amortization (D&A)	86	90	90	89	109	111	85	101	95	104	131
Debt-free, Cash-free Net Working Capital to Revenue	25.25%	25.40%	24.86%	16.66%	20.53%	27.16%	30.42%	27.03%	20.98%	22.91%	25.99%
Debt-free Net Working Capital to Revenue	42.90%	38.07%	40.61%	36.59%	38.04%	41.05%	52.51%	53.15%	45.32%	36.57%	48.53%
Net Working Capital to Revenue	40.53%	33.29%	33.73%	15.10%	35.18%	33.26%	50.55%	31.59%	44.32%	35.79%	26.22%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.33	($1.09)	($0.51)	$0.86	$1.07	$1.51	$1.57	$0.85	$2.27	$2.32	$3.33
Adjusted Weighted Average Basic Shares Outstanding	51.53M	50.91M	51.52M	52.76M	51.53M	50.69M	50.69M	51.05M	50.78M	50.71M	50.33M
Adjusted Diluted Earnings per Share	$0.32	($1.09)	($0.51)	$0.85	$1.04	$1.48	$1.55	$0.84	$2.24	$2.29	$3.31
Adjusted Weighted Average Diluted Shares Outstanding	52.09M	50.91M	51.52M	53.50M	52.94M	51.82M	51.29M	51.35M	51.42M	51.40M	50.73M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	51.68M	51.04M	52.46M	52.21M	51.21M	50.39M	50.95M	51.28M	50.54M	50.84M	48.04M
Normalized Net Operating Profit after Tax (NOPAT)	23	31	27	43	62	135	63	55	127	136	159
Normalized NOPAT Margin	2.56%	3.37%	3.10%	4.75%	6.45%	13.68%	7.22%	5.54%	10.90%	10.37%	11.69%
Pre Tax Income Margin	3.42%	-5.88%	-3.10%	6.60%	7.61%	8.82%	8.38%	6.41%	12.10%	11.60%	15.58%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	231.01%	-109.72%	0.00%	219.43%	290.81%	228.68%	0.00%	0.00%	64.99%	0.00%	134.19%

This table displays calculated financial ratios and metrics derived from Haemonetics' official financial filings.

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Period end date	7/1/2023	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	12/27/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	19.08%	6.96%	10.14%	12.77%	7.98%	8.59%	3.66%	-3.70%	-4.40%	-5.27%	-2.75%
EBITDA Growth	53.11%	-12.76%	1.47%	-3.78%	8.67%	39.06%	21.79%	86.73%	-5.83%	5.07%	7.78%
EBIT Growth	102.36%	-20.04%	4.27%	-28.24%	-9.45%	36.16%	13.37%	202.11%	-3.31%	14.72%	20.15%
NOPAT Growth	77.95%	-29.12%	-3.39%	-17.97%	-23.50%	46.08%	35.91%	124.49%	24.28%	12.77%	13.39%
Net Income Growth	106.48%	-24.97%	-5.17%	-30.68%	-6.50%	35.82%	20.02%	184.68%	-11.32%	14.34%	19.33%
EPS Growth	110.53%	-25.00%	-4.69%	-31.03%	-7.50%	37.50%	21.31%	192.50%	-5.41%	22.73%	28.38%
Operating Cash Flow Growth	-54.55%	13.88%	-100.84%	-19.51%	-243.67%	-50.75%	8,204.81%	81.89%	163.44%	128.01%	113.78%
Free Cash Flow Firm Growth	280.15%	43.49%	-1,831.34%	-6,250.16%	-1,778.60%	-1,777.38%	45.42%	65.30%	102.68%	115.45%	160.24%
Invested Capital Growth	1.39%	-0.05%	22.84%	22.28%	32.79%	38.29%	11.79%	9.43%	1.66%	-1.50%	-2.10%
Revenue Q/Q Growth	2.27%	2.20%	5.68%	2.09%	-2.07%	2.78%	0.88%	-5.15%	-2.78%	1.84%	3.56%
EBITDA Q/Q Growth	30.11%	-25.16%	20.98%	-19.26%	46.95%	-4.23%	5.95%	23.45%	-24.83%	6.85%	8.69%
EBIT Q/Q Growth	58.13%	-36.36%	34.10%	-46.82%	99.51%	-4.30%	11.66%	41.71%	-36.15%	13.54%	16.94%
NOPAT Q/Q Growth	34.45%	-37.26%	21.81%	-20.16%	25.38%	19.80%	13.33%	31.88%	-30.58%	8.70%	13.95%
Net Income Q/Q Growth	39.68%	-39.31%	25.43%	-34.81%	88.41%	-11.84%	10.83%	54.64%	-41.31%	13.67%	15.66%
EPS Q/Q Growth	37.93%	-40.00%	27.08%	-34.43%	85.00%	-10.81%	12.12%	58.11%	-40.17%	15.71%	17.28%
Operating Cash Flow Q/Q Growth	-76.03%	419.35%	-100.54%	11,966.85%	-142.79%	278.05%	-10.36%	166.32%	-85.08%	539.96%	-15.95%
Free Cash Flow Firm Q/Q Growth	685.81%	12.95%	-1,078.16%	1.88%	-54.85%	-12.87%	68.17%	37.62%	111.95%	551.20%	24.08%
Invested Capital Q/Q Growth	3.42%	-2.90%	24.14%	-1.91%	12.31%	1.12%	0.35%	-3.98%	4.33%	-2.02%	-0.26%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	53.73%	53.59%	52.90%	51.24%	52.03%	54.25%	55.53%	58.39%	59.82%	59.50%	59.71%
EBITDA Margin	23.97%	17.55%	20.09%	16.07%	24.12%	22.48%	23.61%	30.73%	23.76%	24.93%	26.16%
Operating Margin	17.24%	11.10%	13.67%	8.72%	11.83%	14.96%	16.94%	21.58%	16.76%	17.87%	19.88%
EBIT Margin	16.57%	10.32%	13.09%	6.82%	13.90%	12.94%	14.32%	21.40%	14.05%	15.67%	17.69%
Profit (Net Income) Margin	13.18%	7.83%	9.29%	5.93%	11.41%	9.79%	10.76%	17.54%	10.59%	11.82%	13.20%
Tax Burden Percent	79.55%	75.87%	70.96%	86.99%	82.15%	75.68%	75.11%	81.97%	75.34%	75.43%	74.60%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	20.45%	24.14%	29.04%	13.01%	17.85%	24.32%	24.89%	18.03%	24.66%	24.57%	25.40%
Return on Invested Capital (ROIC)	12.52%	7.99%	8.39%	6.88%	8.28%	9.91%	10.19%	14.46%	9.45%	9.99%	10.91%
ROIC Less NNEP Spread (ROIC-NNEP)	12.20%	7.61%	8.16%	5.85%	9.13%	9.12%	9.32%	14.40%	8.72%	9.41%	10.29%
Return on Net Nonoperating Assets (RNNOA)	7.72%	4.63%	5.79%	3.66%	7.00%	6.88%	7.96%	12.51%	8.84%	10.09%	9.99%
Return on Equity (ROE)	20.24%	12.63%	14.17%	10.53%	15.29%	16.79%	18.15%	26.98%	18.28%	20.09%	20.90%
Cash Return on Invested Capital (CROIC)	9.55%	10.39%	-11.40%	-11.21%	-20.63%	-23.75%	-2.83%	1.53%	8.52%	12.01%	12.94%
Operating Return on Assets (OROA)	10.68%	6.60%	8.16%	4.32%	8.23%	7.76%	8.31%	12.53%	7.56%	8.38%	9.29%
Return on Assets (ROA)	8.49%	5.01%	5.79%	3.76%	6.76%	5.88%	6.25%	10.27%	5.70%	6.32%	6.93%
Return on Common Equity (ROCE)	20.24%	12.63%	14.17%	10.53%	15.29%	16.79%	18.15%	26.98%	18.28%	20.09%	20.90%
Return on Equity Simple (ROE_SIMPLE)	15.80%	14.35%	13.42%	0.00%	12.69%	14.09%	14.34%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	43	27	33	26	33	39	44	58	41	44	50
NOPAT Margin	13.71%	8.42%	9.70%	7.59%	9.71%	11.32%	12.72%	17.69%	12.63%	13.48%	14.83%
Net Nonoperating Expense Percent (NNEP)	0.32%	0.38%	0.23%	1.02%	-0.84%	0.79%	0.87%	0.06%	0.72%	0.59%	0.63%
Return On Investment Capital (ROIC_SIMPLE)	-	-	1.80%	-	-	-	2.08%	2.86%	1.93%	2.13%	2.35%
Cost of Revenue to Revenue	46.27%	46.41%	47.10%	48.76%	47.97%	45.75%	44.47%	41.61%	40.18%	40.50%	40.29%
SG&A Expenses to Revenue	30.03%	36.24%	33.22%	35.45%	32.20%	30.95%	30.54%	34.83%	34.45%	31.05%	32.20%
R&D to Revenue	4.06%	3.98%	3.95%	4.62%	4.30%	4.78%	4.54%	4.81%	5.06%	4.54%	4.19%
Operating Expenses to Revenue	36.49%	42.49%	39.22%	42.52%	40.21%	39.29%	38.59%	36.82%	43.05%	41.63%	39.82%
Earnings before Interest and Taxes (EBIT)	52	33	44	23	47	45	50	71	45	51	60
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	75	56	68	55	81	78	82	102	76	82	89
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.98	5.08	4.60	4.52	4.65	4.65	4.30	3.87	4.02	2.73	4.12
Price to Tangible Book Value (P/TBV)	32.96	25.56	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.53	3.67	3.42	3.31	3.15	3.00	2.84	2.33	2.63	1.75	2.85
Price to Earnings (P/E)	31.51	35.41	34.28	36.87	36.61	32.99	29.95	18.93	21.70	13.80	21.42
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	3.17%	2.82%	2.92%	2.71%	2.73%	3.03%	3.34%	5.28%	4.61%	7.25%	4.67%
Enterprise Value to Invested Capital (EV/IC)	3.56	3.80	3.10	3.12	2.85	2.78	2.65	2.35	2.47	1.83	2.61
Enterprise Value to Revenue (EV/Rev)	3.92	4.00	3.95	3.79	3.81	3.68	3.49	3.01	3.33	2.45	3.50
Enterprise Value to EBITDA (EV/EBITDA)	18.21	19.47	19.64	19.42	19.40	17.65	16.07	11.95	13.25	9.50	13.27
Enterprise Value to EBIT (EV/EBIT)	28.55	31.10	31.14	32.68	34.60	31.54	29.13	19.30	21.27	14.96	20.33
Enterprise Value to NOPAT (EV/NOPAT)	32.78	36.72	37.50	38.89	43.09	38.40	33.70	23.33	24.46	17.28	23.82
Enterprise Value to Operating Cash Flow (EV/OCF)	19.12	18.89	25.42	27.31	37.60	58.98	37.14	22.52	19.76	11.24	13.63
Enterprise Value to Free Cash Flow (EV/FCFF)	37.51	36.54	0.00	0.00	0.00	0.00	0.00	160.64	29.19	15.11	19.91
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.88	0.85	0.92	0.84	1.35	1.39	1.35	1.49	1.39	1.44	1.34
Long-Term Debt to Equity	0.87	0.84	0.91	0.83	1.35	1.39	1.35	1.12	1.04	1.08	1.01
Financial Leverage	0.63	0.61	0.71	0.62	0.77	0.75	0.85	0.87	1.01	1.07	0.97
Leverage Ratio	2.31	2.39	2.37	2.32	2.54	2.56	2.56	2.61	2.80	2.87	2.76
Compound Leverage Factor	2.31	2.39	2.37	2.32	2.54	2.56	2.56	2.61	2.80	2.87	2.76
Debt to Total Capital	46.94%	46.03%	48.00%	45.70%	57.47%	58.23%	57.46%	59.87%	58.13%	59.05%	57.33%
Short-Term Debt to Total Capital	0.83%	0.82%	0.76%	0.58%	0.24%	0.26%	0.24%	14.84%	14.43%	14.67%	14.27%
Long-Term Debt to Total Capital	46.11%	45.21%	47.24%	45.12%	57.23%	57.97%	57.22%	45.03%	43.70%	44.38%	43.07%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	53.06%	53.97%	52.00%	54.30%	42.53%	41.77%	42.54%	40.13%	41.87%	40.95%	42.67%
Debt to EBITDA	2.91	3.00	3.41	3.16	4.67	4.32	4.10	3.57	3.62	3.58	3.52
Net Debt to EBITDA	1.83	1.62	2.65	2.46	3.35	3.26	3.03	2.68	2.76	2.72	2.47
Long-Term Debt to EBITDA	2.86	2.94	3.36	3.12	4.65	4.30	4.08	2.69	2.73	2.69	2.64
Debt to NOPAT	5.24	5.65	6.51	6.33	10.37	9.39	8.60	6.98	6.69	6.51	6.32
Net Debt to NOPAT	3.29	3.05	5.06	4.93	7.45	7.10	6.35	5.23	5.09	4.94	4.44
Long-Term Debt to NOPAT	5.15	5.55	6.41	6.25	10.33	9.35	8.56	5.25	5.03	4.89	4.74
Altman Z-Score	3.61	3.68	3.21	3.22	2.68	2.61	2.62	2.19	2.34	1.85	2.45
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.38	3.28	2.92	2.56	3.76	3.49	3.97	1.62	1.72	1.64	1.75
Quick Ratio	1.95	1.99	1.55	1.28	2.10	1.87	2.10	0.88	0.93	0.92	1.04
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	24	27	-269	-263	-408	-461	-147	-91	11	71	88
Operating Cash Flow to CapEx	262.21%	1,153.41%	-3.77%	701.57%	0.00%	528.16%	527.62%	883.54%	503.18%	2,273.71%	1,581.27%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.64	0.64	0.62	0.63	0.59	0.60	0.58	0.59	0.54	0.53	0.53
Accounts Receivable Turnover	7.53	7.17	6.47	6.79	7.05	7.02	6.49	6.65	6.69	6.31	6.47
Inventory Turnover	2.04	2.17	2.14	2.14	1.91	1.93	1.93	1.79	1.58	1.54	1.57
Fixed Asset Turnover	4.11	4.03	4.02	4.21	4.40	4.48	4.54	4.57	4.57	4.48	4.52
Accounts Payable Turnover	8.50	8.28	9.92	9.00	8.19	8.64	10.71	8.72	9.43	8.47	9.60
Days Sales Outstanding (DSO)	48.46	50.92	56.42	53.77	51.80	51.99	56.28	54.88	54.54	57.81	56.44
Days Inventory Outstanding (DIO)	178.92	168.19	170.75	170.40	190.64	188.96	188.74	203.52	231.15	236.51	231.87
Days Payable Outstanding (DPO)	42.92	44.08	36.79	40.57	44.59	42.27	34.08	41.86	38.70	43.11	38.04
Cash Conversion Cycle (CCC)	184.46	175.04	190.39	183.60	197.85	198.69	210.94	216.54	246.99	251.21	250.26
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,344	1,305	1,620	1,589	1,785	1,805	1,811	1,739	1,814	1,777	1,773
Invested Capital Turnover	0.91	0.95	0.86	0.91	0.85	0.88	0.80	0.82	0.75	0.74	0.74
Increase / (Decrease) in Invested Capital	18	-0.67	301	290	441	500	191	150	30	-27	-38
Enterprise Value (EV)	4,782	4,954	5,016	4,964	5,085	5,010	4,800	4,093	4,477	3,249	4,619
Market Capitalization	4,303	4,543	4,339	4,335	4,206	4,084	3,896	3,175	3,545	2,321	3,758
Book Value per Share	$17.11	$17.62	$18.59	$18.90	$17.81	$17.17	$18.06	$16.34	$18.37	$17.63	$19.47
Tangible Book Value per Share	$2.58	$3.51	($0.81)	($0.22)	($3.99)	($4.40)	($3.27)	($4.76)	($3.66)	($3.85)	($2.46)
Total Capital	1,630	1,656	1,814	1,768	2,129	2,104	2,132	2,046	2,107	2,074	2,136
Total Debt	765	762	871	808	1,224	1,225	1,225	1,225	1,225	1,225	1,225
Total Long-Term Debt	751	749	857	798	1,218	1,220	1,220	921	921	920	920
Net Debt	479	411	677	629	879	926	904	918	932	928	861
Capital Expenditures (CapEx)	7.28	8.59	14	9.13	-15	9.24	8.30	13	3.46	4.90	5.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)	293	264	323	300	379	388	437	354	393	359	345
Debt-free Net Working Capital (DFNWC)	578	615	517	479	724	687	758	660	686	656	709
Net Working Capital (NWC)	565	602	503	469	719	682	753	357	382	351	404
Net Nonoperating Expense (NNE)	1.65	1.87	1.38	5.68	-5.71	5.29	6.84	0.49	6.56	5.44	5.54
Net Nonoperating Obligations (NNO)	479	411	677	629	879	926	904	918	932	928	861
Total Depreciation and Amortization (D&A)	23	23	24	32	34	33	32	31	31	30	29
Debt-free, Cash-free Net Working Capital to Revenue	24.01%	21.31%	25.43%	22.91%	28.43%	28.51%	31.81%	25.99%	29.18%	27.06%	26.18%
Debt-free Net Working Capital to Revenue	47.45%	49.64%	40.70%	36.57%	54.25%	50.50%	55.17%	48.53%	50.94%	49.38%	53.75%
Net Working Capital to Revenue	46.34%	48.54%	39.62%	35.79%	53.87%	50.10%	54.80%	26.22%	28.36%	26.46%	30.63%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.81	$0.49	$0.62	$0.40	$0.75	$0.66	$0.75	$1.17	$0.71	$0.81	$0.96
Adjusted Weighted Average Basic Shares Outstanding	50.54M	50.73M	50.77M	50.71M	50.94M	50.90M	50.29M	50.33M	48.11M	47.59M	46.79M
Adjusted Diluted Earnings per Share	$0.80	$0.48	$0.61	$0.40	$0.74	$0.66	$0.74	$1.17	$0.70	$0.81	$0.95
Adjusted Weighted Average Diluted Shares Outstanding	51.34M	51.40M	51.45M	51.40M	51.56M	51.24M	50.64M	50.73M	48.35M	47.66M	46.99M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	50.71M	50.74M	50.79M	50.84M	51.18M	50.22M	50.24M	48.04M	48.18M	46.81M	46.47M
Normalized Net Operating Profit after Tax (NOPAT)	43	27	33	26	33	39	44	58	41	51	51
Normalized NOPAT Margin	13.71%	8.42%	9.70%	7.59%	9.71%	11.32%	12.72%	17.69%	12.63%	15.46%	14.99%
Pre Tax Income Margin	16.57%	10.32%	13.09%	6.82%	13.90%	12.94%	14.32%	21.40%	14.05%	15.67%	17.69%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	60.58%	57.66%	134.19%	0.00%	133.78%	128.25%

Financials Breakdown Chart

Key Financial Trends

Below is a concise, investor-focused read on Haemonetics (NYSE: HAE) using the last four years of quarterly statements. The bullets highlight notable trends in revenue, profitability, cash flow, and balance sheet metrics that could influence the stock’s risk/reward for retail investors.

Net income attributable to common shareholders has trended higher across 2024–2025, with a peak in Q4 2025 and continued positive results into 2026.
Operating cash flow from continuing operations has remained solidly positive across recent quarters, underscoring ongoing cash generation.
Gross margin has stayed robust, generally around 58–60% across multiple quarters, signaling stable profitability.
Revenue has been relatively stable in the roughly $320–340 million range, with a modest uptick in 2026 Q3.
Cash and cash equivalents rose to about $363 million by 2026 Q3, and current assets consistently exceed current liabilities, indicating a healthy liquidity cushion.
Quarter-to-quarter profitability shows some seasonality (for example, a notable dip in Q1 2026 after a strong Q4 2025), suggesting quarterly volatility rather than a perfectly steady trend.
Leverage remains moderate and stable, with long-term debt near $0.92 billion and total liabilities around $1.58 billion, leaving room for near-term growth.
Capital expenditures are modest and ongoing, supporting continued investment while preserving overall cash generation.
Investing activities consistently produce net cash outflows, which can weigh on near-term liquidity (e.g., several quarters with meaningful cash used for equipment and investments).

05/21/26 07:51 PM ETAI Generated. May Contain Errors.

Haemonetics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Haemonetics' fiscal year ends in March. Their fiscal year 2025 ended on March 29, 2025.

Haemonetics' net income appears to be on an upward trend, with a most recent value of $167.68 million in 2025, rising from $16.90 million in 2015. The previous period was $117.56 million in 2024. Find out what analysts predict for Haemonetics in the coming months.

Haemonetics' total operating income in 2025 was $221.82 million, based on the following breakdown:

Total Gross Profit: $748.96 million
Total Operating Expenses: $527.14 million

Over the last 10 years, Haemonetics' total revenue changed from $910.37 million in 2015 to $1.36 billion in 2025, a change of 49.5%.

Haemonetics' total liabilities were at $1.63 billion at the end of 2025, a 31.9% increase from 2024, and a 147.3% increase since 2015.

In the past 10 years, Haemonetics' cash and equivalents has ranged from $115.12 million in 2016 to $306.76 million in 2025, and is currently $306.76 million as of their latest financial filing in 2025.

Over the last 10 years, Haemonetics' book value per share changed from 16.04 in 2015 to 16.34 in 2025, a change of 1.8%.

Related Companies

Financial statements for NYSE:HAE last updated on 2/7/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Haemonetics (HAE) Financials

Financials Breakdown Chart

Key Financial Trends

Haemonetics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Haemonetics (HAE) Financials

Annual Income Statements for Haemonetics

Quarterly Income Statements for Haemonetics

Annual Cash Flow Statements for Haemonetics

Quarterly Cash Flow Statements for Haemonetics

Annual Balance Sheets for Haemonetics

Quarterly Balance Sheets for Haemonetics

Annual Metrics And Ratios for Haemonetics

Quarterly Metrics And Ratios for Haemonetics

Financials Breakdown Chart

Key Financial Trends

Haemonetics Financials - Frequently Asked Questions

When does Haemonetics' financial year end?

How has Haemonetics' net income changed over the last 10 years?

What is Haemonetics' operating income?

How has Haemonetics' revenue changed over the last 10 years?

How much debt does Haemonetics have?

How much cash does Haemonetics have?

How has Haemonetics' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools